The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study-Reference-Cited by-同舟云学术

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study

Published:2023-02 Issue: Volume:56 Page:101779
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Ramchandren Radhakrishnan,Johnson Peter,Ghosh Nilanjan,Ruan Jia,Ardeshna Kirit M.,Johnson Roderick,Verhoef Gregor,Cunningham David,de Vos Sven,Kassam Shireen,Fayad Luis,Radford John,Bailly Sarah,Offner Fritz,Morgan David,Munoz Javier,Ping Jerry,Szafer-Glusman Edith,Eckert Karl,Neuenburg Jutta K.,Goy Andre

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Aggressive lymphomas;Lenz;N Engl J Med,2010

2. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte;Feugier;J Clin Oncol,2005

3. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia;Sehn;J Clin Oncol,2005

4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017

5. Chimeric antigen receptor T cells in refractory B-cell lymphomas;Schuster;N Engl J Med,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments;Cureus;2024-08-06

2. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20

3. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial;Nature Communications;2024-03-30

4. Predicting central nervous system relapse in primary breast diffuse large B-cell lymphoma using the stage-modified IPI score: A retrospective cohort study;Heliyon;2024-03

5. Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project;eJHaem;2024-02-23